Oura Delays IPO Amid Market Uncertainty, Valuation Expected Over

Ouraring Inc. sued Ultrahuman and SVTronics Inc. for patent infringement in the U.S. District Court for the Eastern District of Texas, alleging Ultrahuman's Ring Pro infringes its design and utility patents. Oura seeks injunctive relief and damages, including treble damages for willful infringement. This follows an earlier ITC ruling excluding Ultrahuman's Ring Air from the U.S. market.

Oura, a sleep-tracking ring company, postponed its IPO despite a 99% predicted chance, citing market conditions. It reported $1.2B revenue and $60.8M net income for 2026. The delay reflects broader IPO market slowdown, with only 30 U.S. IPOs in Q3 2026, down from 64 in 2025.

Oura postponed its $2.1B IPO citing market uncertainty, despite strong demand. Accelevation (ACCV) priced below range, raising $540M. Roze AI (RZAI) completed direct listing, up 149%. Six SPACs and three IPOs filed. Renaissance IPO Index up 16.4% YTD.

Oura, a smart ring maker, delayed its Nasdaq IPO citing market uncertainty. The company aimed to sell 50M shares, raising up to $2.2B at a $15B valuation. Oura reported strong earnings, with $907.8M revenue and $23.5M pretax profit in fiscal 2025. The delay follows a lawsuit alleging false advertising, but the company denies this influenced the decision.

Oura postponed its $2.2bn IPO, citing market uncertainty despite strong demand. It planned to sell 50M shares at $40-$44 each. The company is profitable, with 5.7M paid members and expects 90% revenue growth in 2026. Four companies postponed IPOs in the same week, according to Renaissance Capital.

Oura, maker of the Oura smart ring, delayed its $2.2B IPO despite strong demand, valuing it at up to $15B. The company planned to offer 50M shares at $40-$44 each but chose to wait due to market conditions. It would have listed on Nasdaq under the ticker OURA.